aura rods

Biotechnology company Seattle Genetics has commenced Phase I trial of a novel antibody-drug conjugate (ADC), SGN-CD33A, in patients with acute myeloid leukaemia (AML).

SGN-CD33A leverages the company’s ADC technology targeted to CD33 antibody, which is attached to a potent cytotoxic DNA-crosslinking agent, a pyrrolobenzodiazepine dimer, by means of a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines.

Seattle Genetics research and translational medicine senior vice-president Jonathan Drachman said SGN-CD33A uses latest technology, combining a highly potent cell-killing agent with a new engineered antibody (EC-mAb) technology that results in uniform drug-loading.

"It is designed to be a highly potent ADC directed to the CD33 antigen, which is found on AML cells," Drachman said.

Designed to assess the safety and anti-leukaemia activity of SGN-CD33A, the open-label, multi-centre, dose-escalation trial will also evaluate pharmacokinetics, progression-free survival and overall survival in patients with CD33-positive AML.

The study’s primary endpoints are the estimation of the maximum tolerated dose and safety assessment of SGN-CD33A.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dose escalation portion of the study will enrol up to approximately 90 patients at multiple centres in the US and evaluate SGN-CD33A administered every three weeks.

Patients achieving a complete remission will continue to obtain SGN-CD33A at a lower, maintenance dose given every three weeks.

The dose escalation cohorts showing evidence of anti-leukaemia activity possibly will be expanded for further safety and clinical activity assessment.

Image: Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Photo: courtesy of VashiDonsk, en.wikipedia.